Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24604444 | 0.74 | OPRM1 (0.35) | OPRM1 | |
| SCHEMBL977558 | 0.73 | HTR2A (0.47) | HTR2ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL4650737 | 0.72 | HTR1A (0.37) | OPRM1 | |
| SCHEMBL27794398 | 0.70 | HTR2A (0.44) | HTR2ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL1334863 | 0.70 | HTR2A (0.44) | HTR2ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL3458741 | 0.70 | HTR2A (0.48) | HTR2ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL136222 | 0.70 | HTR2A (0.44) | HTR2ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL10880855 | 0.70 | HTR2A (0.44) | HTR2ASLC6A2SLC6A4SLC6A3OPRM1 | |
| SCHEMBL28000273 | 0.70 | SLC6A2 (0.39) | HTR2ASLC6A2SLC6A4SLC6A3 | |
| Bromide SCHEMBL5224748 | 0.69 | HTR2A (0.43) | HTR2ASLC6A2SLC6A4SLC6A3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-03-08 | — | — | US | disclosed |
| EP-2406254-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-01-18 | — | — | EP | disclosed |
| EP-2406254-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI (FR) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010104193-A3 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010104193-A2 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059165-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | HRH4, HNMT, CYP3A4 | HTR2A 109/4885SLC6A2 264/4885SLC6A4 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.